Last updated: February 20, 2026
What is Amyvid?
Amyvid (Florbetapir F-18) is an FDA-approved PET imaging agent used to detect amyloid-beta plaques in the brain, aiding in the diagnosis of Alzheimer’s disease (AD). It was developed by Eli Lilly and approved by the FDA in 2012.
Clinical Trials Status and Developments
Current Phase and Ongoing Trials
- No new Phase III trials are publicly registered for Amyvid as of 2023.
- Lilly has focused on expanding the diagnostic application and improving imaging protocols.
- Research explores Amyvid's role in early detection and monitoring of AD progression, with some exploratory studies in mild cognitive impairment (MCI) populations.
Recent Initiatives
- Real-world evidence (RWE) studies: Conducted in collaboration with health systems to understand Amyvid’s impact on diagnosis accuracy.
- Combination diagnostics: Trials investigating Amyvid with other biomarker tools such as tau and neurodegeneration markers.
Patent and Regulatory Trends
- No recent patent filings specific to Amyvid’s imaging agent.
- Future regulatory filings may focus on expanding indications, particularly for early- or pre-symptomatic stages.
Market Analysis
Market Size and Growth Drivers
| Metric |
2023 Data |
2028 Projection |
Compound Annual Growth Rate (CAGR) |
| Global Alzheimer’s diagnostic market |
$2.5 billion |
$4.3 billion |
11.8% |
| Amyloid PET imaging segment |
$1.2 billion |
$2.1 billion |
12.2% |
The market for amyloid PET tracers, including Amyvid, witnesses expansion driven by increased AD prevalence, rising adoption of biomarker-driven diagnostics, and regulatory approvals.
Key Market Players
- Amyvid (Lilly)
- Vizamyl (GE Healthcare): Also uses Flutemetamol.
- Neuraceq (LMI): Uses florbetaben.
Regional Breakdown
| Region |
Market Share (2023) |
Expected Growth (2023–2028) |
| North America |
55% |
11.7% |
| Europe |
25% |
13.0% |
| Asia-Pacific |
15% |
14.5% |
| Rest of World |
5% |
10.2% |
North America leads due to higher AD prevalence, reimbursement infrastructure, and adoption rates.
Reimbursement and Policy Trends
- Medicare in the US reimbursed Amyvid since 2013 with coverage expanded in 2020.
- Pricing per dose averages $1,500–$2,200.
- International reimbursement varies, influencing regional sales.
Market Dynamics and Future Projections
Adoption Drivers
- Growing aging population correlates with increased AD diagnoses.
- Greater clinician familiarity with amyloid imaging improves utilization.
- Evolving guidelines recommend amyloid PET for early diagnosis confirmation.
Barriers
- Cost of imaging limits routine screening.
- Limited availability of PET scanners in some regions.
- Concerns regarding false positives/negatives impact clinical confidence.
Growth Opportunities
- Expansion into early and preclinical stages of AD.
- Integration with disease-modifying therapies awaiting approval.
- Development of simplified, cost-effective imaging protocols.
Revenue Projections
Lilly estimates Amyvid sales reached approximately $265 million in 2022. With an expected CAGR of approximately 12% over five years, revenue could approach $470 million by 2028.
Competitive Landscape
| Compound/Tracer |
Developer |
Approval Year |
Market Share (2023) |
Key Features |
| Amyvid (Florbetapir) |
Lilly |
2012 |
50% |
First FDA-approved amyloid PET agent |
| Vizamyl (Flutemetamol) |
GE Healthcare |
2013 |
25% |
Alternative with different imaging profile |
| Neuraceq (Florbetaben) |
LMI |
2014 |
20% |
Widely used in Europe |
Lilly continues to dominate but faces competition from regional or emerging tracers.
Regulatory Outlook
- Fragmented indications across regions.
- Potential approval for earlier AD stages and asymptomatic populations remains under review.
- Continued data collection to support expansion.
Key Takeaways
- Amyvid remains the leading amyloid PET tracer, with steady market growth expected over the next five years.
- Clinical research emphasizes early detection and integration with other biomarkers but no significant regulatory breakthroughs are imminent.
- Market expansion hinges on increased access to imaging infrastructure, reimbursement policies, and integration into broader diagnostic workflows.
FAQs
1. What are the main clinical applications of Amyvid?
Amyvid is primarily used for detecting amyloid plaques during differential diagnosis of Alzheimer’s disease, especially when clinical presentation alone is inconclusive.
2. Are there any new regulatory updates for Amyvid?
No recent approvals or expanded indications have been announced; focus remains on observational studies and potential early-Stage use.
3. How does Amyvid compare to its competitors?
Amyvid was the first FDA-approved amyloid PET tracer, holding approximately 50% market share as of 2023. It offers high specificity and is well-established, though newer tracers like Neuraceq and Vizamyl provide alternative options with varying regional availability.
4. What factors influence Amyvid’s market growth?
Increased prevalence of AD, broader adoption of biomarker diagnostics, reimbursement policies, and technological advancements in imaging all support growth.
5. What future developments could impact Amyvid’s market position?
Emerging therapies targeting amyloid-beta may drive higher diagnostic testing. Expanded indications for pre-symptomatic diagnosis and technological innovations could further influence sales dynamics.
References
[1] Food and Drug Administration (FDA). (2012). FDA approves first PET scan to help assess brain amyloid plaques linked to Alzheimer’s disease.
[2] MarketWatch. (2023). Alzheimer’s diagnostics market analysis and forecast.
[3] Eli Lilly and Company. (2022). Annual report detailing Amyvid sales and pipeline outlook.
[4] Global Data. (2023). PET imaging tracers market 2023-2028.
[5] U.S. Centers for Medicare & Medicaid Services (CMS). (2020). Reimbursement policies for amyloid PET imaging.
